decisionhealth Newsletters, Coder Pink Sheets - 2006 Issue 3 (March)
Avastin: Off label use not approved by Medicare, get ABN
Subscribe or sign in to view the full article.
Article Overview
This article explains a Medicare reimbursement issue involving off-label ophthalmic use of Avastin and how carriers may treat claims for the drug and related administration. It is aimed at ophthalmology billing staff, coders, and practice administrators who need to understand carrier guidance, patient notice requirements, and the broader coverage context for related drug therapy. The discussion centers on general billing considerations, diagnosis reporting, and Medicare carrier behavior without substituting for the full article.
Why This Topic Matters
Coverage and patient-liability rules can affect whether a practice is paid by Medicare or needs to bill the beneficiary instead. Understanding the article helps coders and billers recognize when carrier policy and advance beneficiary notice requirements may be relevant.
What You Will Learn
- How Medicare carrier coverage may differ for an ophthalmic drug used off label
- Why beneficiary notice requirements matter in this billing scenario
- How the article frames billing and reimbursement issues for the drug and its administration
- How a related approved alternative is discussed in the context of macular degeneration treatment
Who Should Read This
- Medical coders
- Ophthalmology billers
- Practice administrators
- Medicare billing staff
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com